Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine for Thoracic Paravertebral Block in Thoracic Surgery
ChiCTR2500101693Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in postoperative pain comparing Liposomal bupivacaine + ropivacaine, Ropivacaine and Liposomal bupivacaine (3 arms). Primary endpoint: Area under the curve (AUC) of NRS pain intensity score at 0–72 hours postoperatively. Planned start May 2025; status: not yet recruiting.
02
Drugs
bupivacaineropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2500101693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101693.